Акушерство, гинекология и репродукцияIntroduction. Vulvovaginal candidiasis is an extremely common pathology of the female genital organs, leading to a long-term recurrent course and multiple complications.
L. I. Tagirova +11 more
doaj +4 more sources
In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies [PDF]
Journal of Fungi, 2021 Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus
Olga Rivero-Menendez +3 more
doaj +2 more sources
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. [PDF]
Antimicrob Agents ChemotherIbrexafungerp (formerly SCY-078) is the first member of the triterpenoid class that prevents the synthesis of the fungal cell wall polymer β-(1,3)-D-glucan by inhibiting the enzyme glucan synthase.
Gebremariam T +8 more
europepmc +5 more sources
In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures [PDF]
Clinical Microbiology and Infection, 2021 Objectives: Emergence of azole resistance may contribute to recurrences of vulvovaginal candidiasis. Thus, new drugs are needed to improve the therapeutic options.
Escribano, Pilar +7 more
core +5 more sources
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician [PDF]
Infection and Drug Resistance, 2023 Frederic Lamoth1,2 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University ...
Lamoth F
doaj +3 more sources
Our current clinical understanding of Candida biofilms: where are we two decades on? [PDF]
APMIS, Volume 131, Issue 11, Page 636-653, November 2023., 2023 Clinically we have been aware of the concept of Candida biofilms for many decades, though perhaps without the formal designation. Just over 20 years ago the subject emerged on the back of progress made from the bacterial biofilms, and academic progress ...
Borghi, Elisa +5 more
core +4 more sources
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis [PDF]
Infection and Drug ResistanceAnna Zubovskaia, Jose A Vazquez Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta University, Augusta, GA, USACorrespondence: Jose A Vazquez, Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta ...
Zubovskaia A, Vazquez JA
doaj +2 more sources
Ibrexafungerp: A narrative overview
Current Research in Microbial SciencesIbrexafungerp (IBX) is a new antifungal drug that recently entered the antifungal landscape. It disrupts fungal cell wall synthesis by non-competitive inhibition of the β-(1,3)-D-glucan (BDG) synthase enzyme.
L'Emir Wassim El Ayoubi +3 more
doaj +3 more sources
A review of the fernane-type triterpenoids as anti-fungal drugs [PDF]
Frontiers in PharmacologyHuman fungal pathogens could cause a broad plethora of infections in both the immunocompetent and immunocompromised host. Fungal infections have become important causes of morbidity and mortality in recent years, the current arsenal of anti-fungal ...
Chun-Yue Liu +6 more
doaj +2 more sources
The Silent Pandemic: Antifungal Resistance and the Future of Invasive Fungal Disease Management [PDF]
MicroorganismsInvasive fungal diseases (IFDs) represent an escalating global health threat, compounded by the rapid emergence of antifungal resistance (AFR). This review synthesizes the contemporary landscape of AFR from clinical and microbiological perspectives ...
Ruchika Bagga +1 more
doaj +2 more sources